Jeffrey W. Albers, Director at Kymera Therapeutics, Inc. (KYMR), sold 5,000 shares at $59.19 ($296K) on 2025-10-13, disclosed to the SEC on 2025-10-14.
Scheduled sale ($296k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |
| BPMC | SELL | 2025-03-17 | $1.0M | — | Filing → |